Antibody Binding and Angiotensin-Converting Enzyme 2 Binding Inhibition Is Significantly Reduced for Both the BA.1 and BA.2 Omicron Variants
© The Author(s) 2022. Published by Oxford University Press on behalf of Infectious Diseases Society of America..
BACKGROUND: The rapid emergence of the Omicron variant and its large number of mutations led to its classification as a variant of concern (VOC) by the World Health Organization. Subsequently, Omicron evolved into distinct sublineages (eg, BA.1 and BA.2), which currently represent the majority of global infections. Initial studies of the neutralizing response toward BA.1 in convalescent and vaccinated individuals showed a substantial reduction.
METHODS: We assessed antibody (immunoglobulin G [IgG]) binding, ACE2 (angiotensin-converting enzyme 2) binding inhibition, and IgG binding dynamics for the Omicron BA.1 and BA.2 variants compared to a panel of VOCs/variants of interest, in a large cohort (N = 352) of convalescent, vaccinated, and infected and subsequently vaccinated individuals.
RESULTS: While Omicron was capable of efficiently binding to ACE2, antibodies elicited by infection or immunization showed reduced binding capacities and ACE2 binding inhibition compared to wild type. Whereas BA.1 exhibited less IgG binding compared to BA.2, BA.2 showed reduced inhibition of ACE2 binding. Among vaccinated samples, antibody binding to Omicron only improved after administration of a third dose.
CONCLUSIONS: Omicron BA.1 and BA.2 can still efficiently bind to ACE2, while vaccine/infection-derived antibodies can bind to Omicron. The extent of the mutations within both variants prevents a strong inhibitory binding response. As a result, both Omicron variants are able to evade control by preexisting antibodies.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:76 |
|---|---|
| Enthalten in: |
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America - 76(2023), 3 vom: 08. Feb., Seite e240-e249 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Junker, Daniel [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 10.02.2023 Date Revised 20.02.2023 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1093/cid/ciac498 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM342389270 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM342389270 | ||
| 003 | DE-627 | ||
| 005 | 20231226014012.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1093/cid/ciac498 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1141.xml |
| 035 | |a (DE-627)NLM342389270 | ||
| 035 | |a (NLM)35717657 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Junker, Daniel |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Antibody Binding and Angiotensin-Converting Enzyme 2 Binding Inhibition Is Significantly Reduced for Both the BA.1 and BA.2 Omicron Variants |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 10.02.2023 | ||
| 500 | |a Date Revised 20.02.2023 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © The Author(s) 2022. Published by Oxford University Press on behalf of Infectious Diseases Society of America. | ||
| 520 | |a BACKGROUND: The rapid emergence of the Omicron variant and its large number of mutations led to its classification as a variant of concern (VOC) by the World Health Organization. Subsequently, Omicron evolved into distinct sublineages (eg, BA.1 and BA.2), which currently represent the majority of global infections. Initial studies of the neutralizing response toward BA.1 in convalescent and vaccinated individuals showed a substantial reduction | ||
| 520 | |a METHODS: We assessed antibody (immunoglobulin G [IgG]) binding, ACE2 (angiotensin-converting enzyme 2) binding inhibition, and IgG binding dynamics for the Omicron BA.1 and BA.2 variants compared to a panel of VOCs/variants of interest, in a large cohort (N = 352) of convalescent, vaccinated, and infected and subsequently vaccinated individuals | ||
| 520 | |a RESULTS: While Omicron was capable of efficiently binding to ACE2, antibodies elicited by infection or immunization showed reduced binding capacities and ACE2 binding inhibition compared to wild type. Whereas BA.1 exhibited less IgG binding compared to BA.2, BA.2 showed reduced inhibition of ACE2 binding. Among vaccinated samples, antibody binding to Omicron only improved after administration of a third dose | ||
| 520 | |a CONCLUSIONS: Omicron BA.1 and BA.2 can still efficiently bind to ACE2, while vaccine/infection-derived antibodies can bind to Omicron. The extent of the mutations within both variants prevents a strong inhibitory binding response. As a result, both Omicron variants are able to evade control by preexisting antibodies | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Omicron | |
| 650 | 4 | |a SARS-CoV-2 | |
| 650 | 4 | |a antibody binding | |
| 650 | 4 | |a multiplex | |
| 650 | 4 | |a variants of concern | |
| 650 | 7 | |a Angiotensin-Converting Enzyme 2 |2 NLM | |
| 650 | 7 | |a EC 3.4.17.23 |2 NLM | |
| 650 | 7 | |a Immunoglobulin G |2 NLM | |
| 650 | 7 | |a Antibodies, Viral |2 NLM | |
| 650 | 7 | |a Antibodies, Neutralizing |2 NLM | |
| 700 | 1 | |a Becker, Matthias |e verfasserin |4 aut | |
| 700 | 1 | |a Wagner, Teresa R |e verfasserin |4 aut | |
| 700 | 1 | |a Kaiser, Philipp D |e verfasserin |4 aut | |
| 700 | 1 | |a Maier, Sandra |e verfasserin |4 aut | |
| 700 | 1 | |a Grimm, Tanja M |e verfasserin |4 aut | |
| 700 | 1 | |a Griesbaum, Johanna |e verfasserin |4 aut | |
| 700 | 1 | |a Marsall, Patrick |e verfasserin |4 aut | |
| 700 | 1 | |a Gruber, Jens |e verfasserin |4 aut | |
| 700 | 1 | |a Traenkle, Bjoern |e verfasserin |4 aut | |
| 700 | 1 | |a Heinzel, Constanze |e verfasserin |4 aut | |
| 700 | 1 | |a Pinilla, Yudi T |e verfasserin |4 aut | |
| 700 | 1 | |a Held, Jana |e verfasserin |4 aut | |
| 700 | 1 | |a Fendel, Rolf |e verfasserin |4 aut | |
| 700 | 1 | |a Kreidenweiss, Andrea |e verfasserin |4 aut | |
| 700 | 1 | |a Nelde, Annika |e verfasserin |4 aut | |
| 700 | 1 | |a Maringer, Yacine |e verfasserin |4 aut | |
| 700 | 1 | |a Schroeder, Sarah |e verfasserin |4 aut | |
| 700 | 1 | |a Walz, Juliane S |e verfasserin |4 aut | |
| 700 | 1 | |a Althaus, Karina |e verfasserin |4 aut | |
| 700 | 1 | |a Uzun, Gunalp |e verfasserin |4 aut | |
| 700 | 1 | |a Mikus, Marco |e verfasserin |4 aut | |
| 700 | 1 | |a Bakchoul, Tamam |e verfasserin |4 aut | |
| 700 | 1 | |a Schenke-Layland, Katja |e verfasserin |4 aut | |
| 700 | 1 | |a Bunk, Stefanie |e verfasserin |4 aut | |
| 700 | 1 | |a Haeberle, Helene |e verfasserin |4 aut | |
| 700 | 1 | |a Göpel, Siri |e verfasserin |4 aut | |
| 700 | 1 | |a Bitzer, Michael |e verfasserin |4 aut | |
| 700 | 1 | |a Renk, Hanna |e verfasserin |4 aut | |
| 700 | 1 | |a Remppis, Jonathan |e verfasserin |4 aut | |
| 700 | 1 | |a Engel, Corinna |e verfasserin |4 aut | |
| 700 | 1 | |a Franz, Axel R |e verfasserin |4 aut | |
| 700 | 1 | |a Harries, Manuela |e verfasserin |4 aut | |
| 700 | 1 | |a Kessel, Barbora |e verfasserin |4 aut | |
| 700 | 1 | |a Lange, Berit |e verfasserin |4 aut | |
| 700 | 1 | |a Strengert, Monika |e verfasserin |4 aut | |
| 700 | 1 | |a Krause, Gerard |e verfasserin |4 aut | |
| 700 | 1 | |a Zeck, Anne |e verfasserin |4 aut | |
| 700 | 1 | |a Rothbauer, Ulrich |e verfasserin |4 aut | |
| 700 | 1 | |a Dulovic, Alex |e verfasserin |4 aut | |
| 700 | 1 | |a Schneiderhan-Marra, Nicole |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Clinical infectious diseases : an official publication of the Infectious Diseases Society of America |d 1992 |g 76(2023), 3 vom: 08. Feb., Seite e240-e249 |w (DE-627)NLM012603007 |x 1537-6591 |7 nnns |
| 773 | 1 | 8 | |g volume:76 |g year:2023 |g number:3 |g day:08 |g month:02 |g pages:e240-e249 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1093/cid/ciac498 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 76 |j 2023 |e 3 |b 08 |c 02 |h e240-e249 | ||